Skip to main content
. Author manuscript; available in PMC: 2015 Feb 28.
Published in final edited form as: Circ Res. 2014 Feb 28;114(5):754–757. doi: 10.1161/CIRCRESAHA.114.303045

Figure 1. Paradigm shift in Angiotensin research: From vasoactive, short acting hormone to pleiotropic growth factor and immunomodulator.

Figure 1

Dr. Owens findings that Ang II is not just an acute vasoactive substance, but also a potent growth factor inspired multiple new studies in different basic research fields from inflammation to tyrosine kinase signaling. These basic research results served as a starting point for clinical research studies that caused a change in therapeutic practices, with ACE inhibitors and ARBs becoming cornerstone of therapy.